Epidemiology of cutaneous adverse drug reactions

Chemical Immunology and Allergy

Volumn 97, Issue , 2012, Pages 1-17

  Mockenhaupt, Maja ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DICLOFENAC; FUROSEMIDE; HYDROXYCHLOROQUINE; LAMOTRIGINE; MACROLIDE; MELOXICAM; MINOCYCLINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PIROXICAM; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; SULFADIAZINE; SULFADOXINE; SULFAFURAZOLE; SULFONAMIDE; TENOXICAM; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADVERSE DRUG REACTION; ARTICLE; CAUSE OF DEATH; DRESS SYNDROME; DRUG FATALITY; EPIDEMIOLOGICAL DATA; GENETIC EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; MACULOPAPULAR RASH; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; DEMOGRAPHY; EOSINOPHILIA; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; HUMANS; INCIDENCE; ODDS RATIO; PHARMACEUTICAL PREPARATIONS; RISK; STEVENS-JOHNSON SYNDROME; URTICARIA;

EID: 84861445126     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000335612     Document Type: Article

References (36)

1. World Health Organization: International drug monitoring: the role of national centres. World Health Organ Tech Rep Ser 1972;498:1-25.
2. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC: Revised nomenclature for allergy for global use: report of the nomenclature review committee of the World Allergy Organization. October 2003. J Allergy Clin Immunol 2004;113: 832-836.
3. Bork K: Cutaneous Adverse Drug Reactions; in Burgdorf WHC, Plewig G, Wolff HH, Landthaler M (eds): Braun-Falco's Dermatology, ed 3. Heidelberg, Springer, 2009, chapter 33, pp 456-472.
4. Mockenhaupt M: Severe cutaneous adverse reactions; in Burgdorf WHC, Plewig G, Wolff HH, Landthaler M (eds): Braun-Falco's Dermatology, ed 3. Heidelberg, Springer, 2009, chapter 34, pp 473-484.
5. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC for the SCAR Study Group: Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 2002;138:1019-1024.
6. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.
7. Schroder W, Mockenhaupt M, Schlingmann J, Schneck B, Hering O, Schopf E: Clinical Re-classification of severe skin reactions and evaluation of their etiology in a population-based registry; in Victor N, Blettner M, Edler L, Haux R, Knaup-Gregori P, Pritsch M, Wahrendorf J, Windeler J, Ziegler S (eds): Medical informatics, biostatistics and epidemiology for efficient health care and medical research: contributions from the 44th annual conference of the GMDS. Heidelberg, Urban & Vogel, 1999, pp 107-110.
8. Sidoroff A, Halevy S, Bouwes Bavinck JN, Vaillant L, Roujeau JC: Acute generalized exanthematous pustulosis (AGEP) -a clinical reaction pattern. J Cutan Pathol 2001;28:113-119.
9. Sullivan JR, Shear NH: The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001;137:357-362.
10. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC: Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156:609-611.
11. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K: The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156:1083-1084.
12. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V: A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149:1018-1022.
13. Hernandez-Salazar A, Rosales SP, Rangel-Frausto S, Criolio E, Arche-Dubon C, Orozco-Topete R: Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006;37:899-902.
14. Park CS, Kim TB, Kim SL, Kim JY, Yang KA, Bae YJ, Cho YS, Moon HB: The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. Pharmacoepidemiol Drug Saf 2008;17:919-925.
15. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Fléchet ML, Girre JP: Toxic epidermal necrolysis (Lyell's syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126: 37-42.
16. Schöpf E, Stühmer A, Rzany B,Victor N, Zentgraf R, Kapp JF: Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West-Germany. Arch Dermatol 1991;127:839-842.
17. Rzany B, Mockenhaupt M, Baur S, Schröder W, Stocker U, Mueller J, Holländer N, Bruppacher R, Schöpf E: Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). Structure and results of a population-based registry. J Clin Epidemiol 1996;49: 769-773.
18. Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, Correia O, Shapiro S, Kaufman D: An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 1995;48:1099-1108.
19. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schöpf E, Kaufman DW: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Eng J Med 1995;333: 1600-1607.
20. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.
21. Sidoroff A, Dunant A, Viboud C, Halevy S, Bouwes Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC: Risk factors for acute generalized exanthematous pustulosis (AGEP) -results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989-896.
22. Orpha News Europe: the newsletter of the rare disease task force. www.orphanet.net/actor/Europa News/2006/060124.html.
23. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D, Stern RS, Bergmann U, Stolley PD: A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991;127:831-838.
24. Mockenhaupt M, Norgauer J: Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002;14:143-150.
25. Fagot JP, Mockenhaupt M, Bouwes Bavinck JN, Naldi L, Viboud C, Roujeau JC: Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis: preliminary results of a case-control study. AIDS 2001;15:1-6.
26. Mockenhaupt M, Sekula P, Roujeau JC, Sidoroff A, Kardaun S, Liss Y, Bounoua M, the RegiSCAR-study group: Mortality and long-lasting sequelae in patients with severe cutaneous adverse reactions. Pharmacoepidem Dr S 2008;17:115-116.
27. Kardaun SH, Sekula P, Mockenhaupt M, Chu CY, Creamer D, Sidoroff A, Naldi L, Roujeau JC: Drug reaction with eosinophilia and systemic symptoms (DRESS): Results from the RegiSCAR-study. Eur Ann Allergy Clin Immunol 2010;42:45.
28. Thong BV, Leong KP, Tang CY, Chung HH: Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003;90:342-347.
29. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R: Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20 year survey. Allergy 1997;52:388-393.
30. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS: The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003;30:2234-2240.
31. Mockenhaupt M, Messenheimer J, Schlingmann J, Tennis P: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of anti-epileptics. Neurology 2005;64:1134-1138.
32. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, LeLouet H for the RegiSCAR-group: ALDEN an algorithm for assessment of drug causality in Stevens-Johnson-syndrome and toxic epidermal necrolysis. Comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-68.
33. Kauppinen K: Cutaneous reactions to drugs. With special reference to severe bullous mucocutaneous eruptions and sulphonamides. A clinical study. Acta Derm Venereol Suppl 1972;68:1-89.
34. Picard D, Janela B, Descamps V, D'Ibcan M, Jacquot S, Rogez S, Mardivirin L, Moins-Teisserenc H, Toubert A, Benichou J, Joly P, Musette P: Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010;2:46-62.
35. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, et al: HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-1143.
36. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA: Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011;127(3 suppl):60-66. Prof. med.